At the forefront of neuromodulation for SCI
We update our initiation of coverage report on ONWARD, reiterating our BUY rating and raising our PT to EUR 20. ONWARD is a Dutch/Swiss MedTech developing neuromodulation devices to restore movement and function disorders in patients with Spinal Cord Injury (SCI), which has a prevalence of >300k
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.